This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
With sales of $103 million in the fourth quarter and $180 million in its first n...
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mR...
With sales of $103 million in the fourth quarter and $180 million in its first n...
Human medicines European public assessment report (EPAR): Zavicefta, ceftazidime...
Teleflex announced plans to split into two companies—and is setting up one scion...
On BeiGene’s very first live earnings call, CEO and co-founder John Oyler descri...
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Va...
Kallyope has slipped out results from a phase 2 trial of its obesity candidates,...
After receiving a rare pediatric disease priority review voucher in tandem with ...
Disruptions to government-sanctioned advisory committee meetings on vaccines are...
Human medicines European public assessment report (EPAR): mResvia, Single-strand...
The latest biotech updates, brought to you by The Readout newsletter.
A measles death in Texas, another UnitedHealth examination, and other health new...
The FDA canceled an upcoming vaccine advisory committee meeting to discuss influ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Thera...
“While we remain confident in our zerlasiran program for high Lp(a), we will onl...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Human medicines European public assessment report (EPAR): Advagraf, tacrolimus, ...
Even as President Donald Trump wages a very public fight against diversity, equi...
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, D...
Human medicines European public assessment report (EPAR): Welireg, belzutifan, S...
Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib,...
Human medicines European public assessment report (EPAR): Remicade, infliximab, ...
UK drugmaker says Emma Walmsley is underpaid compared with global competitors